We curate a digest of the latest news in our field for advocates, policymakers, community coalitions and all who work toward shaping policies and practices to effectively prevent substance use and treat addiction.
Nonprofit groups that advocate treating pain with medications have received $65 million since 1997 from opioid manufacturers, according to a bipartisan congressional investigation.
Teens’ rate of vaping nicotine and marijuana leveled off this year, but rates remain high, according to the most recent figures from the annual Monitoring the Future survey.
The consulting firm McKinsey & Company advised members of the Sackler family, the owners of OxyContin maker Purdue Pharma, to consider giving the company’s distributors a rebate for every overdose attributable to the pills they sold, according to documents released in a federal bankruptcy court.
Purdue Pharma pleaded guilty to federal criminal charges related to the marketing and distribution of its opioid painkiller OxyContin, The New York Times reports.
Virtual sessions of Alcoholics Anonymous, which have become common during the pandemic, are likely to become a permanent part of recovery, according to participants and addiction treatment providers.
This week a federal bankruptcy judge authorized a settlement valued at $8.3 billion between OxyContin maker Purdue Pharma and the Department of Justice, NPR reports.
Supervising drug consumption at a needle exchange program in Boston would save three to four lives a year, and more than $4 million, according to a new report.
A recent Gallup poll and the passage of state marijuana legalization measures indicate that bipartisan support for legalization is growing, AP reports.
After New York State implemented an excise tax on many opioids in July 2019, some patients have had difficulty filling opioid prescriptions, Kaiser Health News reports.
A large drug company and three major drug distributors have proposed a $26 billion deal with state and local governments that sued them for their role in the opioid crisis. If the deal is finalized, the companies would be shielded from future opioid-related lawsuits from these governments, The New York Times reports.
A new study finds “diseases of despair,” including alcohol and drug misuse and suicidal thoughts and behaviors, rose dramatically in the United States between 2009 and 2018.
A group of Democratic senators is urging the Justice Department to drop its efforts to convert OxyContin maker Purdue Pharma into a public asset, The Wall Street Journal reports.
This website uses cookies. We use cookies and similar technologies to give
you the best experience. By using this website, you accept our Privacy Policy and Terms of Use.